Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Organophosphate And Carbamate Poisoning Overview 6 Therapeutics Development 7 Pipeline Products for Organophosphate And Carbamate Poisoning – Overview 7 Pipeline Products for Organophosphate And Carbamate Poisoning – Comparative Analysis 8 Organophosphate And Carbamate Poisoning – Therapeutics under Development by Companies 9 Organophosphate And Carbamate Poisoning – Therapeutics under Investigation by Universities/Institutes 10 Organophosphate And Carbamate Poisoning – Pipeline Products Glance 11 Early Stage Products 11 Organophosphate And Carbamate Poisoning – Products under Development by Companies 12 Organophosphate And Carbamate Poisoning – Products under Investigation by Universities/Institutes 13 Organophosphate And Carbamate Poisoning – Companies Involved in Therapeutics Development 14 Countervail Corporation 14 Hager Biosciences, LLC 15 Organophosphate And Carbamate Poisoning – Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 AM-132 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 galantamine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PlantVax-1502-H-N - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 RS-194B - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecule for Organophosphate Poisoning - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Activate BuChE for Organophosphate and Carbamate Poisoning - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Organophosphate And Carbamate Poisoning – Discontinued Products 35 Organophosphate And Carbamate Poisoning – Product Development Milestones 36 Featured News & Press Releases 36 Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 37 Disclaimer 38

List of Tables Number of Products under Development for Organophosphate And Carbamate Poisoning, H1 2016 7 Number of Products under Development for Organophosphate And Carbamate Poisoning – Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Organophosphate And Carbamate Poisoning – Pipeline by Countervail Corporation, H1 2016 14 Organophosphate And Carbamate Poisoning – Pipeline by Hager Biosciences, LLC, H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Organophosphate And Carbamate Poisoning – Discontinued Products, H1 2016 35 List of Figures Number of Products under Development for Organophosphate And Carbamate Poisoning, H1 2016 7 Number of Products under Development for Organophosphate And Carbamate Poisoning – Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Targets, H1 2016 17 Number of Products by Stage and Targets, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 19 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 21 Number of Products by Molecule Types, H1 2016 23 Number of Products by Stage and Molecule Types, H1 2016 23

Countervail Corporation Hager Biosciences, LLC